This Changes Everything for Benefits Leaders with Fiduciary Duty
A Johnson & Johnson employee filed a class action lawsuit on February 5, 2024, sending shockwaves through the benefits community. Alleging breach of fiduciary duty by the company, the lawsuit exposes alarming markups in prescription drug costs within the company’s health plan. Some of these markups are as high as 801% markup for an HIV drug, a 6,392% markup for a prostate cancer drug, a 9,592% markup for a leukemia drug, and a 12,403% markup for an MS drug. Despite hiring top benefit consultants and PBMs, serious mismanagement occurred, raising serious concerns about benefit management practices.
Together with Vivio, Frier Levitt co-founding partner Jonathan Levitt and CEO of Vivio Pramod John will present a webinar, “Breaking: J&J ERISA Employee Benefit Lawsuit. Am I at Risk?” on Wednesday, February 21, 2024 at 1pm EST. During this webinar, the panelists will delve into the class action, answering the following question:
- Is this lawsuit a big deal?
- Am I at personal risk?
- Could my company be sued?
- What should I do?
Who should attend? Self-funded employers, benefits consultants and employee benefits professionals.
Can’t attend the live session? Register anyway, and we will send you a recording of the webinar. Additionally, all webinar registrants will receive a White Paper with further details.
Co-Managing Partner
